Cell No. : Cell Name
RCB0659 : HOUA-I
update : 2022/03/18
|
| Comment | Human cell line derived from uterine cancer (endometrial cancer). |
| Comment from the depositor | |
| Terms and conditions | There is no restriction regarding use for basic researches. In relation to commercial use and use for patent filing, first of all please contact the RIKEN BRC. |
| Remarks | |
| Order Form |
Order Form(C-0005.pdf)
MTA(C-0007.pdf)
MTA(C-0007p.pdf)
|
|
Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, not-for-profit academic purpose (C-XXXX) and for-profit research purpose (C-XXXXp) , depending on the sort of user institutions and the purposes of use. Please use an appropriate MTA(to see). In relation to commercial use and use for patent filing, first of all Please contact RIKEN BRC (cellbank.brc@riken.jp).
|
|
|
Basic information
|
Depositor |
Ishiwata, Isamu
|
| Originator |
Ishiwata, Isamu
|
| Year of deposit |
1991
|
| Animal |
human
< Mammals
|
| Genus |
Homo
|
| Species |
sapiens
|
| Gender |
Female
|
| Age at sampling |
55 years
|
| Tissue |
endometrium
|
| Disease name |
Endometrial adenocarcinoma
|
| Classification |
cancer
|
| Year of origin |
1982
|
|
Lifespan |
infinite
|
| Morphology |
epithelial-like
|
| Cellosaurus(Expasy) |
CVCL_3867
|
|
| |
deposit info |
lot info |
|
Medium |
Medium List |
|
Culture type |
|
Adherent cells
|
| Medium and additives |
|
HamF12 + 15% FBS
|
| Antibiotics |
|
Free
|
|
Passage method |
|
0.25% Trypsin
|
Culture information
|
Passage ratio |
|
1 : 8 split
|
| SC frequency |
|
Subculture : once/3-4 weeks, Medium Renewal : 2 times/week
|
| Temperature |
|
37
℃
|
| CO2 concentration |
|
5
%
|
| Freeze medium |
|
Medium + 10% DMSO
|
| Freezing method |
|
Slow freezing
|
| Mycoplasma |
|
(-)
|
| Virus (HIV) |
|
(-)
|
| Isozyme |
|
LD, NP
|
| Chromosome mode |
|
43-92(50) : /44(1),45(10),46(19),47(3),48(3),49(1)/
|
| STR(human) |
|
OK
|
| Images |
deposit info | lot info |
|
|
|
| Reference information |
Reference |
1
|
| User's Publication |
7
|
| User's Publication |
|
13927
Xu D, Dong P, Xiong Y, Chen R, Konno Y, Ihira K, Yue J, Watari H.
PD-L1 Is a Tumor Suppressor in Aggressive Endometrial Cancer Cells and Its Expression Is Regulated by miR-216a and lncRNA MEG3
Front Cell Dev Biol
2020
8:598205
PubMed ID: 33363153
|
|
14241
Ihira K, Dong P, Xiong Y, Watari H, Konno Y, Hanley SJ, Noguchi M, Hirata N, Suizu F, Yamada T, Kudo M, Sakuragi N.
EZH2 inhibition suppresses endometrial cancer progression via miR-361/Twist axis
Oncotarget
2017
8(8):13509-13520
PubMed ID: 28088786
|
|
7708
Dong P, Kaneuchi M, Watari H, Hamada J, Sudo S, Ju J, Sakuragi N.
MicroRNA-194 inhibits epithelial to mesenchymal transition of endometrial cancer cells by targeting oncogene BMI-1.
Mol. Cancer
2011
10:99
PubMed ID: 21851624
|
|
8772
Sugimoto T, Koizumi T, Sudo T, Yamaguchi S, Kojima A, Kumagai S, Nishimura R.
Correlative expression of cyclooxygenase-1 (Cox-1) and human epidermal growth factor receptor type-2 (Her-2) in endometrial cancer.
Kobe J Med Sci
2008
53:177-87
PubMed ID: 18204294
|
|
13831
Unoki M, Nakamura Y.
Methylation at CpG islands in intron 1 of EGR2 confers enhancer-like activity
FEBS Lett
2003
554(1-2):67-72
PubMed ID: 14596916
|
|
3101
Matsushima-Nishiu M, Unoki M, Ono K, Tsunoda T, Minaguchi T, Kuramoto H, Nishida M, Satoh T, Tanaka T, Nakamura Y
Growth and gene expression profile analyses of endometrial cancer cells expressing exogenous PTEN.
Cancer Res
2001
61:3741-9
PubMed ID: 11325847
|
|
1902
Shu Qin Liu, Kaoru Saijo, Makoto Kodama, Tadao Ohno
Intelligent matrices for tumor-specific cytotoxic T lymphocytes
Materials Science and Engineering: C
1994
2:61-65
|
Back
Top
CELL BANK Website
